menu
    • menu
    [{"orgOrder":0,"company":"Tubulis","sponsor":"BioMedPartners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"TUB-010","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Tubulis \/ BioMedPartners","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ BioMedPartners"},{"orgOrder":0,"company":"Tubulis","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"TUB-010","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tubulis \/ Tubulis","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ Tubulis"},{"orgOrder":0,"company":"Tubulis","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Series B Financing","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Tubulis \/ Andera Partners","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ Andera Partners"},{"orgOrder":0,"company":"Tubulis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":1.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.02,"dosageForm":"","sponsorNew":"Tubulis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Tubulis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"TUB-040","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Tubulis \/ EQT Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ EQT Life Sciences"},{"orgOrder":0,"company":"Tubulis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TUB-040","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tubulis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Not Applicable"},{"orgOrder":0,"company":"Tubulis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"TUB-040","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tubulis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Not Applicable"},{"orgOrder":0,"company":"Tubulis","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tubulis","amount2":0.44,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"","sponsorNew":"Tubulis \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Tubulis \/ Gilead Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Tubulis

    Menu

    Tubulis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Gilead Sciences

                            Deal Size : $435.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Gilead Taps German biotech Tubulis for Solid Tumor ADC Development Deal Worth up to $465M

                            Details : The agreement aims to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target using Tubulis’ proprietary Tubutecan and Alco5 platforms.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $20.0 million

                            December 03, 2024

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Gilead Sciences

                            Deal Size : $435.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tubulis Receives FDA Fast Track for TUB-040 in Platinum-resistant Ovarian Cancer

                            Details : TUB-040, a novel Napi2b-targeting ADC-based product., which is being evaluated for the treatment of patients with Ovarian Cancer and Non-small Cell Lung Cancer.

                            Brand Name : TUB-040

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 27, 2024

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tubulis Begins Phase I/IIa Trial of TUB-040 in Cancer

                            Details : TUB-040, a novel Napi2b-targeting ADC, is being evaluated in the Phase II clinical trial studies for the treatment of Ovarian Cancer and Non-small Cell Lung Cancer.

                            Brand Name : TUB-040

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 20, 2024

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : EQT Life Sciences

                            Deal Size : $138.8 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Tubulis Rides Wave of ADC Interest to $138M Financing Round

                            Details : The financing aims to support Tubulis' ongoing clinical development of TUB-040, a novel Napi2b-targeting ADC-based product being evaluated in Phase II trials for ovarian cancer & NSCLC.

                            Brand Name : TUB-040

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 14, 2024

                            Lead Product(s) : TUB-040

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : EQT Life Sciences

                            Deal Size : $138.8 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,022.7 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for th...

                            Details : Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis’ Tubutecan payloads in combination with Tubulis’ proprietary P5 conjugation platform for the development of a selected number of highly differentiated AD...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $22.7 million

                            April 19, 2023

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,022.7 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Andera Partners

                            Deal Size : $63.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Andera Partners Supports Tubulis in a €60 Million Series B Financing to Accelerate the Development of its AD...

                            Details : The proceeds will enable the company to deliver the true therapeutic potential of antibody drug conjugates (ADCs) through further innovation of novel payload classes and identification of new cancer targets.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 03, 2022

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Andera Partners

                            Deal Size : $63.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-010

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : WuXi Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Tubulis Partners with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates

                            Details : WuXi Biologics and WuXi STA will perform scale-up, process development and GMP manufacturing for the ADC product intermediates. The first program from Tubulis’ pipeline the companies will collaborate on is TUB-010.

                            Brand Name : TUB-010

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 02, 2020

                            Lead Product(s) : TUB-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : WuXi Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed

                            Tubulis

                            Germany arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TUB-010

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : BioMedPartners

                            Deal Size : $12.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

                            Details : The funds will be used to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company.

                            Brand Name : TUB-010

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 21, 2020

                            Lead Product(s) : TUB-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : BioMedPartners

                            Deal Size : $12.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth